![logo](/logos/RGNX.webp)
REGENXBIO Inc.
NASDAQ:RGNX
11.48 (USD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | REGENXBIO Inc. |
Symbool | RGNX |
Munteenheid | USD |
Prijs | 11.48 |
Beurswaarde | 567,378,336 |
Dividendpercentage | 0% |
52-weken bereik | 10.49 - 28.8 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Kenneth T. Mills |
Website | https://www.regenxbio.com |
An error occurred while fetching data.
Over REGENXBIO Inc.
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform,
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)